FDA Approval Sought for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma

A rolling new drug application seeking the approval of tovorafenib monotherapy for the treatment of patients with relapsed or progressive pediatric low-grade glioma has been submitted to the FDA.

Related Keywords

Jeremy Bender , ,Response Assessment ,Neuro Oncology High Grade Glioma ,Day One Biopharmaceuticals ,Day One ,Pediatric Neuro Oncology Low Grade Glioma ,Neuro Oncology Low Grade Glioma ,Brain Cancer ,Low Grade Glioma ,Fda ,Braf V600e ,Tovorafenib ,